Literature DB >> 28795649

Immunotherapy of cancers comes of age.

Hila Yousefi1,2, Jianda Yuan3, Mahsa Keshavarz-Fathi1,4,5, Joseph F Murphy6, Nima Rezaei1,7,8.   

Abstract

INTRODUCTION: Cancer immunotherapy has evolved and is aimed at generating the efficacious therapeutic modality to enhance the specificity and power of the immune system to combat tumors. Areas covered: Current efforts in cancer immunotherapy fall into three main approaches. One approach is through the blockade of immune checkpoints, another approach is through adoptive cellular therapy, and the last approach is through vaccination. The goal of this review is to summarize the current understanding and status of cancer immunotherapy in these three categories. Expert commentary: We foresee the development of therapeutic protocols combining these approaches with each other or conventional therapies to achieve the most appropriate guideline for management of cancer.

Entities:  

Keywords:  Cancer immunotherapy; adoptive cellular therapy; bispecific antibodies; chimeric antigen receptors; dendritic cell; immune checkpoint blockade; therapeutic cancer vaccine

Mesh:

Substances:

Year:  2017        PMID: 28795649     DOI: 10.1080/1744666X.2017.1366315

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  30 in total

Review 1.  Advances in engineering local drug delivery systems for cancer immunotherapy.

Authors:  Peter Abdou; Zejun Wang; Qian Chen; Amanda Chan; Daojia R Zhou; Vivienne Gunadhi; Zhen Gu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-04-07

Review 2.  Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer.

Authors:  Nathan Singh; Junwei Shi; Carl H June; Marco Ruella
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952

3.  Reovirus: Friend and Foe.

Authors:  Michael R Eledge; Marcelle Dina Zita; Karl W Boehme
Journal:  Curr Clin Microbiol Rep       Date:  2019-07-04

Review 4.  Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.

Authors:  Mengling Wu; Qianrui Huang; Yao Xie; Xuyi Wu; Hongbo Ma; Yiwen Zhang; Yong Xia
Journal:  J Hematol Oncol       Date:  2022-03-12       Impact factor: 17.388

Review 5.  A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors.

Authors:  Neeraj Chhabra; Joseph Kennedy
Journal:  J Med Toxicol       Date:  2021-04-07

6.  Circulating Lymphocyte Counts Early During Radiation Therapy Are Associated With Recurrence in Pediatric Medulloblastoma.

Authors:  Clemens Grassberger; Daniel Shinnick; Beow Y Yeap; Mark Tracy; Susannah G Ellsworth; Clayton B Hess; Elizabeth A Weyman; Sara L Gallotto; Miranda P Lawell; Benjamin Bajaj; David H Ebb; Myrsini Ioakeim-Ioannidou; Jay S Loeffler; Shannon M MacDonald; Nancy J Tarbell; Torunn I Yock
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-02-05       Impact factor: 8.013

Review 7.  Novel Immunotherapeutic Approaches for Neuroblastoma and Malignant Melanoma.

Authors:  Fabio Morandi; Francesco Frassoni; Mirco Ponzoni; Chiara Brignole
Journal:  J Immunol Res       Date:  2018-10-30       Impact factor: 4.818

Review 8.  Overcoming Barriers of Age to Enhance Efficacy of Cancer Immunotherapy: The Clout of the Extracellular Matrix.

Authors:  Mark Owyong; Gizem Efe; Michael Owyong; Aamna J Abbasi; Vaishnavi Sitarama; Vicki Plaks
Journal:  Front Cell Dev Biol       Date:  2018-03-01

9.  Low Lymphocyte Count Is Associated With Radiotherapy Parameters and Affects the Outcomes of Esophageal Squamous Cell Carcinoma Patients.

Authors:  Xin Wang; Zongxing Zhao; Peiliang Wang; Xiaotao Geng; Liqiong Zhu; Minghuan Li
Journal:  Front Oncol       Date:  2020-06-23       Impact factor: 6.244

10.  Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis.

Authors:  Xian Shen; Bin Zhao
Journal:  BMJ       Date:  2018-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.